Introduction
 The Clinical Trials Unit (CTU) has now moved to its new accommodation in the Beatson West of Scotland Cancer Centre on the Gartnavel campus.The recent success in winning funding for new studies has resulted in an expansion of projects and staffing in the CTU such that we have already filled this enhanced space.
We have also been awarded Experimental Cancer Medicine Centre funding to replace (and increase) our NTRAC support.This will enhance our abilities to perform truly translational studies in humans.
It has proved difficult to restructure and recruit in the wake of Bob Brown’s departure to Imperial College but we have refocused the Gene Medicines programme.
Email:
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
 Link to Cassidy Scientific Report 2008 152.82 Kb
Recent Publications
Lindsay CR, MacPherson IR, Cassidy J (2009). Current status of cediranib: the rapid development of a novel anti-angiogenic therapy.
Future Oncol. 5, 421-32.
Cassidy J, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A,
Wong R, Koski S, Lichinitser M,Yang TS, Rivera F, Couture F,
Sirzen F, Saltz L (2008). Randomized phase III study of capecitabine
plus oxaliplatin compared with fluorouracil/folinic acid plus
oxaliplatin as first-line therapy for metastatic colorectal
cancer. J Clin Oncol. 26, 2006-12.
Espie CA, Fleming L, Cassidy J, Samuel L,Taylor LM,White
CA, Douglas NJ, Engleman HM, Kelly HL, Paul J (2008).
Randomized controlled clinical effectiveness trial of cognitive
behavior therapy compared with treatment as usual for
persistent insomnia in patients with cancer. J Clin
Oncol. 26, 4651-8.
Graham JS, Plummer R, McCoy C, Kowal K,Wiesinger H,
Detjen K, Calvert H,Wiedenmann B, Cassidy J (2008). Open-label,
non-randomised, inter-individual dose escalation of ZK
304709 with the evaluation of safety, tolerability,
pharmacokinetics, oral bioavailability and orientating efficacy
after daily administration in patients with advanced cancer (7
d treatment and 14 d recovery). Eur J Cancer 44, 2162-8.
Guo XX, Goessl E, Collie-Duguid ESR, Cassidy J,Wang
WG, O’Brien V (2008). Cell cycle perturbation and acquired 5-
fluorouracil chemoresistance. Anti-Cancer Res. 28,
9-14.
Saltz LB, Clarke S, Diaz-Rubio E, Scheithauer W, Figer A,
Wong R, Koski S, Lichinitser M,Yang TS, Rivera F, Couture F,
Sirzen F, Cassidy J (2008). Bevacizumab in combination with
oxaliplatin-based chemotherapy as first-line therapy in
metastatic colorectal cancer: A randomized phase III study.
J Clin Oncol. 26, 2013-9.
Sharp L, Little J, Brockton NT, Cotton SC, Masson LF,
Haites NE, Cassidy J (2008). Polymorphisms in the
methylenetetrahydrofolate reductase (MTHFR) gene, intakes
of folate and related B vitamins and colorectal cancer: A
case-control study in a population with relatively low folate
intake. Br J Nutr 99, 379-89.
Cassidy J (2008). Optimizing oxaliplatin-based therapy in metastatic
colorectal cancer. Clin Adv in Hematol & Oncol.
6, 360-1.
Cassidy J (2008). Radio-chemotherapy in rectal cancer. Eur J Cancer 44, 1620-1.
Cassidy J (2008). Cetuximab for the treatment of patients with
colorectal cancer. Nat Clin Pract Oncol. 5,
310-1.
Cassidy J, Schmoll HJ,Van Cutsem E (2008). Pharmacoeconomic
benefits of capecitabine-based chemotherapy in metastatic
colorectal cancer. J Clin Oncol. 26, 226-7.
Glen H, Cassidy J (2008). Redefining adjuvant chemotherapy in
patients with stage III colon cancer: X-ACT trial. Expert
Rev of Anticancer Ther. 8, 547-51.
Haller DG, Cassidy J, Clarke SJ, Cunningham D,Van Cutsem
E, Hoff PM, Rothenberg ML, Saltz LB, Schmoll HJ,Allegra C,
Bertino JR, Douillard JY, Gustavsson BG, Milano G,
O’Connell M, Rustum Y,Tabernero J, Gilberg F, Sirzen F,
Twelves C (2008). Potential regional differences for the tolerability
profiles of fluoropyrimidines. J Clin Oncol. 26, 2118-23.
Macpherson IRJ, Cassidy J (2008). Challenges in combinational
oncology studies. Pharm Med. 22, 85-97.
Benson C, White J, De Bono J, O’Donnell A, Raynaud F, Cruickshank C, McGrath H, Walton M, Workman P, Kaye S, Cassidy J, Gianella-Borradori A, Judson I, Twelves C (2007). A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 96, 29-37.
Guo X, Evans TR, Somanath S, Armesilla AL, Darling JL, Schatzlein A, Cassidy J, Wang W (2007). In vitro evaluation of cancer-specific NF-kappaB-CEA enhancer-promoter system for 5-fluorouracil prodrug gene therapy in colon cancer cell lines. Br J Cancer 97, 745-54.
Hanauske AR, Cassidy J, Sastre J, Bolling C, Jones RJ, Rakhit A, Fettner S, Brennscheidt U, Feyereislova A, Diaz-Rubio E (2007). Phase 1b dose escalation study of erlotinib in combination with infusional 5-fluorouracil, leucovorin, and oxaliplatin in patients with advanced solid tumors. Clin Cancer Res. 13, 523-31.
Macleod A, Branch A, Cassidy J, McDonald A,
Mohammed N, Macdonald L (2007). A nurse-
/pharmacy-led capecitabine clinic for colorectal
cancer: results of a prospective audit and
retrospective survey of patient experiences.
Eur J Oncol Nurs. 11, 247-54.
Wang W, McLeod HL, Cassidy J, Collie-Duguid ES. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks (2007). Cancer Chemother & Pharmacol. 59, 839-45.
Cassidy J (2007). Why patient representation might harm science?
Breast Cancer Res. 9, S4.
Cassidy J (2007). Is breast cancer advocacy distorting the cancer
budget to the disadvantage of other tumours? Breast Cancer
Res. 9, S6.
Cassidy J (2007). Which first-line treatment is superior in advanced colorectal cancer: XELOX or pviFOX? Nat Clin Pract Oncol. 4, 280-1.
Kelly C, Cassidy J (2007). Chemotherapy in metastatic colorectal cancer. Surg Oncol. 16, 65-70.
Kelly C, Cassidy J (2007). Capecitabine in the treatment of colorectal cancer. Expert Rev in Anticancer Ther. 7, 803-10.
Cassidy J (2006). Did you skip the lectures? Eur J Cancer 42, 2860-1.
Cassidy J, Douillard JY, Twelves C, McKendrick JJ, Scheithauer W, Bustova I,
Johnston PG, Lesniewski-Kmak K, Jelic S,
Fountzilas G, Coxon F, Diaz-Rubio E,
Maughan TS, Malzyner A, Bertetto O, Beham
A, Figer A, Dufour P, Patel KK, Cowell W,
Garrison LP (2006). Pharmacoeconomic analysis of
adjuvant oral capecitabine vs intravenous 5-FU/LV
in Dukes’ C colon cancer: the X-ACT trial. Br
J Cancer 94, 1122-9
Glen H, Cassidy J (2006). Vitamin D (and its analogs) in
the treatment and prevention of cancer. Expert
Rev. in Anticancer Ther. 6, 305-8.
Kearney N, Kidd L, Miller M, Sage M,
Khorrami J, McGee M, Cassidy J, Niven K,
Gray P (2006). Utilising handheld computers to monitor
and support patients receiving chemotherapy:
results of a UK-based feasibility study. Supportive
Care in Cancer 14, 742-52.
Robinson HM, Jones R, Walker M, Zachos G,
Brown R, Cassidy J, Gillespie DA (2006). Chk1-
dependent slowing of S-phase progression protects
DT40 B-lymphoma cells against killing by the
nucleoside analogue 5-fluorouracil. Oncogene 25, 5359-69.
Rustin GJ, Timmers P, Nelstrop A, Shreeves G,
Bentzen SM, Baron B, Piccart MJ, Bertelsen K,
Stuart G, Cassidy J, Eisenhauer E (2006). Comparison
of CA-125 and standard definitions of progression
of ovarian cancer in the intergroup trial of cisplatin
and paclitaxel versus cisplatin and
cyclophosphamide. J Clin Oncol. 24, 45-51.
|
